Abstract:

Anti-epidermal growth factor receptor（EGFR） monoclonal antibody is an important therapy for patients with metastatic colorectal cancer（mCRC）. However， due to the presence of intrinsic resistance and the development of acquired resistance， the response rate of antiEGFR monoclonal antibodies（anti-EGFR mAb） is not satisfied. According to the molecular alteration， this review elaborates with the molecular mechanisms of anti-EGFR mAb in mCRC， providing a reference for further studying on the resistance mechanisms of anti-EGFR mAb and a theoretical basis for individualized therapy in patients with mCRC.